Andere Sprachen Rhythm Pharmaceuticals, Inc.

Aktien

A2H5A0

US76243J1051

RYTM

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:30:56 02.05.2024			% 5 Tage	% 1. Jan.
41,16 ^USD	-0,64 %		+7,86 %	-10,49 %

30.04.	Rhythm Pharmaceuticals, Inc. gibt die Veröffentlichung der Ergebnisse der Phase-2-Studie mit Setmelanotid zur Behandlung der hypothalamischen Adipositas in der Fachzeitschrift Lancet Diabetes & Endocrinology bekannt	CI
18.04.	RHYTHM PHARMACEUTICALS, INC. : Wells Fargo Securities bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology	30.04.
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	30.04.
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024	24.04.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	16.04.
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	01.04.
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing	01.04.
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, C2 Life Sciences, Llc, Perceptive Discovery ID LP	01.04.
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy	25.03.
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	25.03.
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	25.03.
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	25.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	22.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	22.03.
Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals	20.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	20.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20.03.
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	20.03.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants	11.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Rhythm Pharmaceuticals, Inc.

Aktien

A2H5A0

US76243J1051

RYTM

Andere Sprachen

Filter